Fabrizio Chiti Selected Research

squalamine

1/2022	Squalamine and trodusquemine: two natural products for neurodegenerative diseases, from physical chemistry to the clinic.
1/2017	A natural product inhibits the initiation of α-synuclein aggregation and suppresses its toxicity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Fabrizio Chiti Research Topics

Disease

29	Neurodegenerative Diseases (Neurodegenerative Disease) 09/2023 - 07/2005
26	Alzheimer Disease (Alzheimer's Disease) 03/2024 - 04/2002
20	Amyloidosis 09/2023 - 03/2002
11	Parkinson Disease (Parkinson's Disease) 04/2024 - 12/2002
11	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 12/2022 - 01/2014
11	Neuroblastoma 08/2022 - 01/2014
8	Amyloid Plaque 08/2022 - 12/2002
7	Proteostasis Deficiencies 02/2024 - 05/2012
4	Frontotemporal Dementia (Semantic Dementia) 12/2022 - 01/2014
3	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 07/2022 - 10/2019
2	TDP-43 Proteinopathies 12/2023 - 07/2019
2	Dementia (Dementias) 01/2021 - 10/2020
2	Paralysis (Palsy) 01/2018 - 01/2017
2	Cardiomyopathies (Cardiomyopathy) 10/2017 - 04/2016
2	Familial Amyloid Neuropathies (Familial Amyloid Polyneuropathy) 10/2017 - 04/2016
2	Neoplasms (Cancer) 09/2016 - 09/2015
2	Brain Diseases (Brain Disorder) 07/2011 - 04/2002
1	Synucleinopathies 01/2023
1	Body Weight (Weight, Body) 12/2022
1	Disease Progression 08/2022
1	Transthyretin-Related Hereditary Amyloidosis 01/2022
1	Nervous System Diseases (Neurological Disorders) 01/2018
1	Familial Amyloidosis (Hereditary Amyloidosis) 10/2017
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 09/2016
1	Cognitive Dysfunction 08/2013
1	Type 2 Diabetes Mellitus (MODY) 07/2011
1	Necrosis 03/2005
1	Creutzfeldt-Jakob Syndrome (Creutzfeldt-Jakob Disease) 12/2002

Drug/Important Bio-Agent (IBA)

43	Proteins (Proteins, Gene)FDA Link 03/2024 - 04/2002
36	Amyloid (Amyloid Fibrils)IBA 04/2024 - 03/2002
20	Peptides (Polypeptides)IBA 01/2023 - 12/2002
11	SynucleinsIBA 04/2024 - 01/2014
6	24-dihydroxy-5-cholestane 24-sulfate 3-N-1(spermine)-7IBA 02/2023 - 01/2018
6	DNA-Binding Proteins (DNA Binding Protein)IBA 12/2022 - 01/2016
5	Prealbumin (Transthyretin)IBA 01/2019 - 12/2013
5	Protein AggregatesIBA 01/2018 - 03/2005
4	Profilins (Profilin)IBA 01/2018 - 07/2015
3	UbiquitinIBA 07/2022 - 01/2014
2	Amyloid beta-PeptidesIBA 01/2023 - 04/2010
2	squalamineIBA 01/2022 - 01/2017
2	LipidsIBA 01/2021 - 01/2017
2	NucleophosminIBA 09/2016 - 09/2015
2	Heparitin Sulfate (Heparan Sulfate)IBA 04/2012 - 10/2009
1	Biomarkers (Surrogate Marker)IBA 03/2024
1	Single-Domain AntibodiesIBA 01/2024
1	Coloring Agents (Dyes)IBA 12/2023
1	SolventsIBA 02/2023
1	Amyloidogenic ProteinsIBA 01/2023
1	LigandsIBA 08/2022
1	tafamidisIBA 01/2022
1	AMPA Receptors (AMPA Receptor)IBA 01/2021
1	CalciumIBA 01/2021
1	N-Methylaspartate (NMDA)IBA 01/2021
1	Unilamellar LiposomesIBA 11/2020
1	PrionsIBA 10/2020
1	Nuclear Proteins (Protein, Nuclear)IBA 08/2020
1	Proteasome Endopeptidase Complex (Proteasome)IBA 07/2019
1	Thyroid HormonesIBA 01/2019
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2019
1	AntibodiesIBA 01/2019
1	Vitamin A (Retinol)FDA LinkGeneric 01/2019
1	Intrinsically Disordered ProteinsIBA 01/2018
1	IonsIBA 01/2017
1	GangliosidesIBA 01/2017
1	Muramidase (Lysozyme)IBA 11/2016
1	Indicators and Reagents (Reagents)IBA 01/2016
1	BromidesIBA 09/2015
1	peptide AIBA 07/2014
1	Histocompatibility Antigens Class IIBA 10/2013
1	GlycosaminoglycansIBA 10/2009
1	alpha-SynucleinIBA 07/2005

Therapy/Procedure

1	Therapeutics 04/2016